| abstract |
The invention relates to a process for the preparation of an inhibitor of angiotensin converting enzyme for the treatment of hypertension. The object of the invention is to provide a new inhibitor which can be applied to all patients, regardless of the form of administration and without side effects. According to the invention, compounds of the general formula in which R is hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl, pyro-L-glutamyl-L are prepared as novel inhibitors. lysyl, L-lysyl, L-arginyl or pyro-L-glutamyl, A is L-phenylalanyl (or D, L-phenylalanyl), D-phenylalanyl, D, L-alanyl, D-alanyl, D, L-tryptophyl, D, L-tyrosyl, D-tyrosyl, D, L-isoleucyl, D-isoleucyl, D, L-leucyl, D-leucyl, D, L-histidyl, D-histidyl, D, L-valyl or D -valyl , R deep 1 is hydrogen or methyl, R deep 2 L-proline, L-3,4-dehydroproline, D, L-3,4-dehydroproline, L-3-hydroxyproline, L-4-hydroxyproline, L-thiazolidine 4-carboxylic acid or L-5-oxo-proline and the imino group of these radicals is linked to the adjacent group in imide bond and n is O or 1 and here R deep 1 is methyl when n is O. |